WallStreetZenWallStreetZen

NASDAQ: CABA
Cabaletta Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CABA

Based on 7 analysts offering 12 month price targets for Cabaletta Bio Inc

Min Forecast
$3.00+50.75%
Avg Forecast
$14.43+625.08%
Max Forecast
$25.00+1,156.28%

Should I buy or sell CABA stock?

Based on 7 analysts offering ratings for Cabaletta Bio Inc.

Strong Buy
Strong Buy
4 analysts 57.14%
Buy
1 analysts 14.29%
Hold
2 analysts 28.57%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CABA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CABA as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their CABA stock forecasts and price targets.

CABA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-11
lockedlocked$00.00+00.00%2025-05-16
lockedlocked$00.00+00.00%2025-05-16
lockedlocked$00.00+00.00%2025-04-01
lockedlocked$00.00+00.00%2025-04-01
Morgan Stanley
Top 10%
91
Strong BuyMaintains$22.00+1,005.53%2025-04-01
Evercore ISI Group
Bottom 5%
5
HoldDowngrades$6.00+201.51%2024-12-20

1 of 1

Forecast return on equity

Is CABA forecast to generate an efficient return?

Company
-95.18%
Industry
140.86%
Market
89.98%
CABA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CABA forecast to generate an efficient return on assets?

Company
-70.06%
Industry
32.43%
CABA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CABA earnings per share forecast

What is CABA's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.51
Avg 2 year Forecast
-$2.41
Avg 3 year Forecast
-$2.69

CABA revenue forecast

What is CABA's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$22.9M
Avg 2 year Forecast
$203.9M
Avg 3 year Forecast
$598.7M

CABA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CABA$1.99$14.43+625.08%Strong Buy
GUTS$2.06$10.00+385.44%Strong Buy
OKYO$3.01$7.00+132.56%Buy
SAVA$2.05$2.00-2.44%Hold
CRBU$1.11$7.00+530.63%Strong Buy
View Top Biotech Stocks

Cabaletta Bio Stock Forecast FAQ

Is Cabaletta Bio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: CABA) stock is to Strong Buy CABA stock.

Out of 7 analysts, 4 (57.14%) are recommending CABA as a Strong Buy, 1 (14.29%) are recommending CABA as a Buy, 2 (28.57%) are recommending CABA as a Hold, 0 (0%) are recommending CABA as a Sell, and 0 (0%) are recommending CABA as a Strong Sell.

If you're new to stock investing, here's how to buy Cabaletta Bio stock.

What is CABA's earnings growth forecast for 2025-2027?

(NASDAQ: CABA) Cabaletta Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.

Cabaletta Bio's earnings in 2025 is -$126,760,000.On average, 5 Wall Street analysts forecast CABA's earnings for 2025 to be -$127,365,184, with the lowest CABA earnings forecast at -$150,199,579, and the highest CABA earnings forecast at -$70,025,479. On average, 5 Wall Street analysts forecast CABA's earnings for 2026 to be -$122,392,360, with the lowest CABA earnings forecast at -$159,333,337, and the highest CABA earnings forecast at -$48,205,946.

In 2027, CABA is forecast to generate -$136,498,942 in earnings, with the lowest earnings forecast at -$154,766,458 and the highest earnings forecast at -$123,305,735.

What is CABA's revenue growth forecast for 2028-2030?

(NASDAQ: CABA) Cabaletta Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.

Cabaletta Bio's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast CABA's revenue for 2028 to be $1,161,255,866, with the lowest CABA revenue forecast at $805,293,013, and the highest CABA revenue forecast at $1,517,218,720. On average, 2 Wall Street analysts forecast CABA's revenue for 2029 to be $10,344,234,854, with the lowest CABA revenue forecast at $8,905,921,657, and the highest CABA revenue forecast at $11,782,548,052.

In 2030, CABA is forecast to generate $30,380,402,000 in revenue, with the lowest revenue forecast at $26,701,019,746 and the highest revenue forecast at $34,059,784,253.

What is CABA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CABA) forecast ROA is -70.06%, which is lower than the forecast US Biotechnology industry average of 32.43%.

What is CABA's Price Target?

According to 7 Wall Street analysts that have issued a 1 year CABA price target, the average CABA price target is $14.43, with the highest CABA stock price forecast at $25.00 and the lowest CABA stock price forecast at $3.00.

On average, Wall Street analysts predict that Cabaletta Bio's share price could reach $14.43 by Jun 11, 2026. The average Cabaletta Bio stock price prediction forecasts a potential upside of 625.08% from the current CABA share price of $1.99.

What is CABA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CABA) Cabaletta Bio's current Earnings Per Share (EPS) is -$2.54. On average, analysts forecast that CABA's EPS will be -$2.51 for 2025, with the lowest EPS forecast at -$2.96, and the highest EPS forecast at -$1.38. On average, analysts forecast that CABA's EPS will be -$2.41 for 2026, with the lowest EPS forecast at -$3.14, and the highest EPS forecast at -$0.95. In 2027, CABA's EPS is forecast to hit -$2.69 (min: -$3.05, max: -$2.43).

What is CABA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CABA) forecast ROE is -95.18%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.